Rockwell Medical: HC Wainwright & Co. maintains a 'Buy' Rating, The Target Price is $2.5

HC Wainwright & Co. maintains 'Buy' rating on Rockwell Medical(RMTI).

The target price is $2.5, compare with $3 previously.

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2025-11-13	HC Wainwright & Co.	Maintains	Buy	Buy	$2.5	$3

[Recent Earning Results] Rockwell Medical posted the Q3 of its 2025 financial results on 11/12/2025, reporting total revenue of USD 50.91 million in the first three quarters, down 33.73% from USD 76.82 million year over year, reporting net income of USD -4.76 million in the first three quarters, compare with USD 0.28 million in the same period last year.

[Company Profile] Rockwell Medical, Inc., incorporated in the state of Michigan in 1996 and re-domiciled to the state of Delaware in 2019. Rockwell Medical is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell is a revenue-generating business and the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed at freestanding outpatient dialysis centers, at hospital-based outpatient centers, at skilled nursing facilities, or in a patient's home. Rockwell manufactures hemodialysis concentrates under Current Good Manufacturing Practices ("cGMP") regulations at its three facilities in Michigan, Texas, and South Carolina totaling approximately 175,000 square feet, and manufactures dry acid concentrate mixers at its facility in Iowa. Rockwell delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally utilizing its own delivery trucks and third-party carriers.